Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28

Aligos Therapeutics, Inc. (NASDAQ:ALGS) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.28 and last traded at $8.40, with a volume of 36620 shares. The stock had previously closed at $9.14.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Friday.

Aligos Therapeutics Price Performance

The stock has a market capitalization of $609.26 million, a price-to-earnings ratio of -6.68 and a beta of 2.18. The firm has a fifty day moving average of $13.19 and a 200 day moving average of $16.19.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of ($4.00) by $4.75. The firm had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same period last year, the firm earned ($10.75) earnings per share. Research analysts predict that Aligos Therapeutics, Inc. will post -8.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC increased its stake in shares of Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $861,000. Altitude Crest Partners Inc. purchased a new position in shares of Aligos Therapeutics in the fourth quarter valued at approximately $1,889,000. Finally, Armistice Capital LLC boosted its stake in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after acquiring an additional 363,000 shares during the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).